April 2024 in “Dermatology and therapy” There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.
June 2019 in “Journal of Dermatological Treatment” BM-PHA is as effective and safe as Restylane Perlane for improving nasolabial folds with minor side effects.
Baricitinib is more effective than methotrexate for severe alopecia areata.
110 citations
,
October 2013 in “The Journal of Sexual Medicine” Testosterone treatment in trans men increases body and facial hair and may lead to hair loss over time, but severe skin issues are rare.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
8 citations
,
April 2006 in “Acta dermato-venereologica” Dovobet ointment used overnight effectively reduces scalp psoriasis severity and itch.
2 citations
,
August 2020 in “Journal of Cosmetic Dermatology” Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
1 citations
,
May 2017 in “Journal of The American Academy of Dermatology” People with alopecia areata often have lower vitamin D levels than healthy people.
November 2025 in “The Bioscan.” Pix Liquida may help treat alopecia areata.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” A nurse-led hair service reduced waiting times and improved patient satisfaction and outcomes for alopecia areata treatment.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
December 2022 in “The Indian journal of chest diseases & allied sciences” Women with PCOS often have sleep problems, including sleep apnea, which are linked to obesity and depression.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
94 citations
,
September 2008 in “Journal of the American Academy of Dermatology” Traction alopecia is more common in African women than girls, especially when traction is applied to chemically relaxed hair; avoiding such hairstyles may reduce the risk.
8 citations
,
November 2022 in “Cureus” Lulican™ shampoo is more effective and better tolerated than Ketoconazole for treating scalp seborrheic dermatitis.
STS01 1% effectively promotes hair regrowth with minimal side effects.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
39 citations
,
November 2017 in “Journal of The American Academy of Dermatology” The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
29 citations
,
June 2013 in “Journal of the Saudi Society of Dermatology & Dermatologic Surgery” Alopecia areata is an autoimmune hair loss condition treated with corticosteroids, and histologic confirmation is the best diagnosis method.
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
2 citations
,
January 2018 in “International journal of research in dermatology” Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
Monthly PRP therapy is more effective than daily minoxidil for alopecia areata.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.